Equities Analysts Issue Forecasts for ACAD FY2026 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Kim forecasts that the biopharmaceutical company will post earnings of $0.85 per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share.

ACAD has been the topic of several other research reports. HC Wainwright raised their price objective on ACADIA Pharmaceuticals from $27.00 to $32.00 and gave the stock a "buy" rating in a research note on Monday, May 19th. Needham & Company LLC increased their price target on ACADIA Pharmaceuticals from $27.00 to $30.00 and gave the stock a "buy" rating in a report on Monday, May 19th. UBS Group dropped their price target on ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating on the stock in a research report on Monday, April 28th. Oppenheimer reissued a "market perform" rating on shares of ACADIA Pharmaceuticals in a research note on Friday, May 16th. Finally, Robert W. Baird raised their target price on shares of ACADIA Pharmaceuticals from $28.00 to $31.00 and gave the stock an "outperform" rating in a report on Monday, May 19th. Six analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $26.79.

ACADIA Pharmaceuticals Price Performance

ACAD traded down $0.10 during mid-day trading on Tuesday, hitting $22.20. The stock had a trading volume of 1,878,945 shares, compared to its average volume of 1,938,876. The stock's fifty day simple moving average is $17.47 and its 200-day simple moving average is $17.70. The firm has a market capitalization of $3.72 billion, a price-to-earnings ratio of 28.46 and a beta of 0.65. ACADIA Pharmaceuticals has a 1-year low of $13.40 and a 1-year high of $25.23.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The business had revenue of $244.32 million for the quarter, compared to the consensus estimate of $239.32 million. During the same period last year, the company posted $0.10 EPS. ACADIA Pharmaceuticals's revenue for the quarter was up 18.7% on a year-over-year basis.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, insider James Kihara sold 4,000 shares of the stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $22.50, for a total value of $90,000.00. Following the transaction, the insider now directly owns 20,395 shares of the company's stock, valued at $458,887.50. This represents a 16.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mark C. Schneyer sold 3,498 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $14.60, for a total value of $51,070.80. Following the completion of the sale, the executive vice president now owns 62,773 shares of the company's stock, valued at $916,485.80. This trade represents a 5.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 33,273 shares of company stock worth $653,182. 26.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ACAD. Assenagon Asset Management S.A. bought a new position in ACADIA Pharmaceuticals during the first quarter worth about $60,845,000. Point72 Asset Management L.P. acquired a new position in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $40,935,000. American Century Companies Inc. increased its holdings in shares of ACADIA Pharmaceuticals by 1,055.8% during the first quarter. American Century Companies Inc. now owns 1,632,749 shares of the biopharmaceutical company's stock worth $27,120,000 after purchasing an additional 1,491,484 shares during the period. Norges Bank acquired a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $25,555,000. Finally, Nuveen LLC bought a new stake in shares of ACADIA Pharmaceuticals in the first quarter valued at approximately $21,630,000. Institutional investors and hedge funds own 96.71% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.